But does the vaccine completely protect against corona, or does the infection contain mild symptoms? Will masks and social remote action be distributed after a certain percentage of injections?
Lisa O’Neill, Global Media Relations Director at Sky News Arabia’s Faizer, answered a number of important questions.
– How long does the vaccine against the emerging corona virus last?
“This is a question we continue to explore, but it’s clear that the possibility of a seasonal vaccine option is likely to occur. Before reaching any conclusions, there is much to learn about the disease, virus, and preventive nature of vaccines currently being developed.”
In a statement to Sky News Arabia, the company said: “We do not know how the virus will change and how long the vaccine’s preventive effect will last. It’s important to take. ” The good news is that mRNAs have the most opportunity to do both.
“MRNA” or “messenger RNA” technology is based on the programming of human cells to replicate part of a virus, which aims to stimulate the immune system to attack when the real virus enters the body.
Can we discuss preventive measures and social remoteness after vaccinating a certain percentage of the population?
Since each country or region has its own situation and preventive measures, Pfizer told Sky News Arabia that “every country can have public health officials answer this question.”
–Does the vaccine protect us from contracting the virus, or are we infected with fewer symptoms?
“Last week we released the full efficacy data of our third phase clinical trial, which showed that the vaccine was 95 percent effective in helping prevent covid-19. According to the company, 28 days after receiving the first dose.
Faizer explained that the vaccine “shows consistent efficacy among people regardless of age, gender or race.” “The effectiveness of the vaccine exceeds 94 percent in people 65 years of age and older.”
What are the side effects of the vaccine?
Faizer said the data showed that it was “safe among different populations” and that “there were more than 43,000 participants in the trial and no serious security concerns were found.”
The company explained that the only two reported symptoms were “fatigue 3.8 percent and headache 2 percent”.
Pfizer had previously announced that it expects to produce up to 50 million doses this year, enough to protect 25 million people and by 1.21 billion doses by 2021.